Literature DB >> 6359572

An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease.

N Bergsdorf, T Nilsson, P Wallén.   

Abstract

Utilizing the immunoglobulin fraction from a goat antiserum against human uterine tissue plasminogen activator, an enzyme-linked immunoassay for tissue-type plasminogen activator in human plasma has been developed. With the new method, the concentration of t-PA in normal human acidified plasma is found to be 4.0 +/- 1.8 (SD) ng/ml. It increases to 12 ng/ml after a tourniquet test, and to 14 ng/ml after strenuous physical exercise. In a group of patients with idiopathic thromboembolic disease, the resting t-PA concentration was 5 ng/ml and the post-occlusion value 16 ng/ml. Furthermore, the patients also exhibited a normal post-occlusion rise in the concentration of plasmin-alpha 2-antiplasmin complex. However, in 37% of the post-occlusion patient plasmas, virtually no increase in t-PA could be detected by a specific activity assay. The results indicate that the reason for a defective post-occlusion fibrinolytic activity in a majority of cases may be the presence of increased concentrations of a fast-acting specific t-PA inhibitor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6359572

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol.

Authors:  J H Jansson; B Johansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Consumption of fibrinolytic proteins in menstrual fluid from women with normal menstrual blood loss.

Authors:  S A Cederholm-Williams; M C Rees; A C Turnbull
Journal:  J Clin Pathol       Date:  1984-08       Impact factor: 3.411

3.  Binding of tissue plasminogen activator to cultured human endothelial cells.

Authors:  K A Hajjar; N M Hamel; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

4.  [Anti-phospholipid antibody with recurrent venous thromboembolism and severe autoimmune thrombocytopenia].

Authors:  J Kienast; H Ostermann; W Stenzinger; E M Kötter; J van de Loo
Journal:  Klin Wochenschr       Date:  1989-07-03

5.  Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.

Authors:  D J Fitzgerald; G A Fitzgerald
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

6.  Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.

Authors:  R Sawaya; R F Highsmith
Journal:  J Neurooncol       Date:  1992-10       Impact factor: 4.130

7.  Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.

Authors:  J H Jansson; K Boman; T K Nilsson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

Authors:  J Aznar; A Estellés; G Tormo; P Sapena; V Tormo; S Blanch; F España
Journal:  Br Heart J       Date:  1988-05

9.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

10.  Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.

Authors:  F Violi; D Ferro; M Saliola; C Quintarelli; S Basili; F Balsano
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.